CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...